目的 检测胰腺癌患者CCL25/CCR9的表达情况,并结合临床病理资料分析CCL25/CCR9对原发性胰腺癌临床预后的影响.方法 搜集2006年1月至2008年1月手术切除的58例胰腺癌患者的癌组织和引流淋巴结以及10例胰腺良性肿瘤的蜡块标本.采用免疫组化方法检测上述标本CCL25/CCR9蛋白表达情况;同时复习临床资料,分析胰腺癌患者CCL25/CCR9表达情况与预后的关系.结果 免疫组化结果显示,在胰腺良性病变、胰腺癌及胰腺癌引流淋巴结中的阳性率:CCL25分别为40.0%、62.1%、91.4%,组间表达存在差异(X2=19.31,P<0.05);CCR9分别为40.0%、79.3%、86.2%,组间表达存在差异(x2=11.12,P<0.05).胰腺癌淋巴结转移组的CCL25阳性表达率(87.1%)高于无淋巴结转移组(63.0%),胰腺癌淋巴结转移组的CCR9阳性表达率(90.3%)高于无淋巴结转移组(66.7%);且随着癌细胞分化程度的降低和TNM分期的增加,CCL25/CCR9表达均增加(P<0.05).CCL25/CCR9阳性胰腺癌患者生存率较阴性组低.结论 CCL25/CCR9与胰腺癌的发生发展有关,可作为评估胰腺癌患者预后的相关指标,具有一定的临床指导意义.%Objective To investigate the expressions of CCL25 and CCR9 in pancreatic cancer and tumor draining lymph nodes (TDLNs) , and to find out the relationship between the expressions of CCL25/CCR9 and the prognosis of pancreatic cancer. Methods 58 patients with pancreatic cancer and 10 patients with pancreatic benign diseases who received resectional surgery were studied from Jan 2006 to Jan 2008. Immunohistochemistry was used to detect the expressions of CCL25 and CCR9 in pancreatic cancer,TDLNs and benign diseases. Result Immunohistochemistry showed that the positive rate of CCR9 in TDLNs (86. 2%) was higher than in pancreatic cancer (79. 3%) (P<0. 05),which in turn was higher than benign diseases (40%) (P<0. 05). The positive rates of CCL25 in TDLNs, pancreatic cancer and benign diseases were 91.4% (53/58), 62.1% (36/58) , 40% (4/10),respectively. The expressions of CCL25/CCR9 protein in pancreatic cancer was associated with the clinical stage and the pathological type. There was significant difference in the survival time between the CCL25/CCR9 positive and negative patients (P<0. 05). Conclusions The expressions of CCL25/CCR9 were increased in pancreatic cancer and TDLNs, which suggested that CCL25/CCR9 might be involved in pancreatic cancer metastasis. CCL25/CCR9 might be regarded as an important marker in the prognosis.
展开▼
